(Q33569106)

28 July 2017

1 reference

title

Prescribing trends and pharmacoeconomic considerations in the treatment of arrhythmias. Focus on atrial fibrillation and flutter (English)

1 reference

28 July 2017

0 references

Phillips BG

1

1 reference

28 July 2017

Bauman JL

series ordinal

2

1 reference

28 July 2017

publication date

1 June 1995

1 reference

28 July 2017

1 reference

28 July 2017

volume

7

1 reference

28 July 2017

issue

6

1 reference

28 July 2017

page(s)

521-533

1 reference

Preliminary report of the Stroke Prevention in Atrial Fibrillation Study

28 July 2017

cites work

1 reference

12 December 2020

Outpatient antiarrhythmic drug use from 1970 through 1986

1 reference

12 December 2020

How the university cardiologist treats ventricular premature beats: a nationwide survey of 65 University Medical Centers

1 reference

12 December 2020

Verapamil infusions in the treatment of atrial tachyarrhythmias

1 reference

12 December 2020

Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter. The Diltiazem-Atrial Fibrillation/Flutter Study Group

1 reference

12 December 2020

Physician practice in the management of patients with uncomplicated myocardial infarction: changes in the past decade

1 reference

12 December 2020

Treatment of ventricular arrhythmias by United States cardiologists: a survey before the cardiac arrhythmia suppression trial results were available

1 reference

12 December 2020

A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: a multicenter study

1 reference

12 December 2020

Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter

1 reference

12 December 2020

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

1 reference

12 December 2020

Pharmacoeconomic considerations in antiarrhythmic therapy

1 reference

12 December 2020

Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.

1 reference

12 December 2020

Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators

1 reference

12 December 2020

Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome) by radiofrequency current

1 reference

12 December 2020

Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.

1 reference

12 December 2020

Effectiveness and costs of digoxin treatment for atrial fibrillation and flutter

1 reference

12 December 2020

Stroke Prevention in Atrial Fibrillation Study. Final results

1 reference

12 December 2020

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study

1 reference

12 December 2020

The surgical treatment of atrial fibrillation. III. Development of a definitive surgical procedure

1 reference

12 December 2020

Treatment of Supraventricular Tachycardia Due to Atrioventricular Nodal Reentry by Radiofrequency Catheter Ablation of Slow-Pathway Conduction

1 reference

12 December 2020

1 reference

12 December 2020

Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective

1 reference

12 December 2020

Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study

1 reference

12 December 2020

10.2165/00019053-199507060-00006

Identifiers

DOI

1 reference

Dimensions Publication ID

28 July 2017

1001542842

0 references

1 reference